Gina Raimondo is Considering Another Run for Governor of Rhode Island

The Democrat is nearing the end of her tenure as U.S. Commerce secretary

Raimondo during an event in Middletown in May.
Raimondo during an event in Middletown in May.
The Public’s Radio
Share
Raimondo during an event in Middletown in May.
Raimondo during an event in Middletown in May.
The Public’s Radio
Gina Raimondo is Considering Another Run for Governor of Rhode Island
Copy

Former Rhode Island Gov. Gina Raimondo — a Democrat who is facing the end of her tenure as U.S. Commerce secretary due to Donald Trump’s victory last week — is considering making another run for governor, The Public’s Radio has learned from multiple sources.

Speculation on Raimondo’s future has centered on the possibility of her taking a high-level corporate job or possibly a university presidency.

But according to a source familiar with her thinking, Raimondo, 53, has examined the constitutionality of making a third run for governor and is considering it with the idea that an elective position could help propel her back into national politics. Another source confirmed that a run for governor is among Raimondo’s possible future options.

This story was reported by The Public’s Radio. You can read the entire story here.

“Growth and innovation is the shape of the tradition that I’m a part of, and it asks that of me constantly”
We highlight a few of the many events happening across the Community Libraries of Providence – from a bilingual theater workshop to your chance to make a giant cyanotype image from vintage Apollo mission moon photographs. Plus: the Smith Hill block party
Health officials say an East Providence mosquito tested positive for West Nile Virus, urging residents to use repellent and eliminate standing water as mosquito season ramps up.
Rhode Island Attorney General Peter Neronha says new funding plans aim to resolve a multimillion-dollar gap and secure the future of the long-struggling CharterCARE hospitals
The Woonsocket-based health care giant reported $98.9 billion in revenue, boosted by higher prescription volume and a 39% jump in health insurance income, sending shares up 8% in premarket trading